


UPDATE

VALUE RANGE

USD 6.68 – 7.03



PPTA (lighter line) Nasdaq market vs price relative

Tuesday, 07 March 2023

Intrinsic Price (USD)	6.86
Value Range Low (USD)	6.68
Value Range High (USD)	7.03
Implied MCAP (m)	452.26
Implied EV (m)	416.29
XNAS	PPTA
TSX	PPTA
Financial YE	31-Dec
Currency	USD

Business Activity

Close Price (USD)

Mining E&P

Key Metrics

224.32
-36.21
188.11
4.88
1.69
-16.14%

3.56

1.00

Mining Sector Research Nasdaq Market Index Analyst Team

FX Rate USD/USD

+44 20 7419 7928 mining@acfequityresearch.com

Perpetua Resources Corp

Filling the US Critical Minerals Supply Gap

Perpetua Resources Corp. (Nasdaq: PPTA; TSX: PPTA) is an Idaho based (Stibnite jurisdiction), gold-antimony-silver (Au-Sb-Ag) junior explorer/producer. ACF is releasing a valuation increase for PPTA based on milestones achieved since our initiation note. ACF identifies PPTA as a US national strategic asset (Sb) and best-in-class gold asset. On Dec 19, 2022 PPTA received a critical minerals award from the DoD of up to \$24.8m for environmental/engineering studies to complete FEIS, RoD/permits and advance year-1 construction readiness. PPTA is an ESG leader amongst junior miners (long run lower WACC). PPTA holds a unique antimony (Sb) reserve in the US and is positioned to be the only domestically mined source of Sb (supplying ~35% of domestic demand).

- DoD \$24.8m award under Defense Production Act;
- SDEIS comment period closed on-time (January 10, 2023);
- Au: Proven & Probable Reserves at 4.8 Moz gold (Au) @ 1.43 g/t;
- Sb: Proven & Probable Reserves 148 Mlbs at 0.06% in 104 Mt;
- Ambri Inc. partnership for antimony-based liquid battery.

ACF est. \$ (m)	Revenue	EBITDA	EPS (diluted)	CPS	CPS (diluted)
2027E	628.0	435.4	4.79	6.91	6.60
2031E	1,123.6	876.6	7.43	13.91	13.29
Multiples	EV/	EV/	P/ EPS	P/	P/ CPS
iviuitipies	Revenue	EBITDA	(diluted)	CPS	(diluted)
2027E	0.3x	0.43x	0.74x	0.52x	0.54x
2031E	0.2x	0.2x	0.5x	0.3x	0.3x



	No. of	
	Shares in	Fully
Share Price History	issue	diluted
NoSh (m)	63.01	65.97
Implied Intrinsic Price	7.18	6.86
Value Range Low	6.82	6.68
Value Range High	7.54	7.03
XNAS	PPTA	
Financial YE	31-Dec	
Reporting Currency	USD	
NoSh (m)		63.01
No Ch (a) accorded		62.04
NoSh (m) expected		63.01
dilution (Exp D)		
NoSh (m) full dilution (FD)		65.97
		00.07
Key Metrics	\$	adj.
MCAP (m)	224.3	224.3
Net Debt (Cash) (m)	(36.2)	(36.2)
EV (m)	188.1	188.1
52 Wk Hi	4.88	4.88
52 Wk Lo	1.69	1.69
Free Float	26%	26%
*Key Metrics FCF adj.	2027E	2031E
CPS (USD)	6.91	13.9
CPS (Exp D) (USD)	6.91	13.9
CPS (FD) (USD)	6.60	13.3
P/CPS	0.52x	0.26x
P/CPS (Exp D)	0.52x	0.26x
P/CPS (FD)	0.52x	0.20x 0.27x
1/013(10)	0.348	0.278

Investment Case

Perpetua Resources Corp, an ESG/sustainability focused junior miner is redeveloping the Stibnite Gold Project (SGP), Idaho, previously abandoned after 100+ years of mining activity. PPTA's SGP boasts high grade gold @ 2.2 g/t (est. years 1-4 with M + I resource of 6 Moz Au @ 1.42 g/t). The 2020 feasibility study (FS) suggests superior economics with a post-tax NPV of \$1.86bn (assumptions: 5% discount rate, gold \$1,850/oz) and will be the only domestic mined source of the critical mineral Sb (M+I 206Mlbs @0.07%).

Top tier gold mine – PPTA completed a feasibility study (FS) on the Stibnite Gold Project in Dec 2020. The FS recorded Proven & Probable Reserves at 4.8 Moz gold (Au) @ 1.43 g/t, Measure and Indicated (M + I) at 6.0 Moz @ 1.42 g/t. In contrast, we conservatively model Proven & Probable at Au 4.25 Moz by reducing grade assumptions by 5% as a margin of error vs. the FS.

The FS provides evidence that Stibnite is one of the largest independent gold projects in the US. Stibnite could become the second largest gold producing mine in the US with an average annual production of 463 Koz years 1-4. We conservatively model average annual production of 457 Koz years 1-4. The project's exceptional grade and low strip ratio place it in the lowest quartile of the mining cost curve (AISC cost at \$438/oz in years 1-4).

The FS suggests robust project economics of 22% IRR at \$1,600/oz gold and ~28% IRR at \$1,850/oz gold. We assume an aggressive >11.6% WACC and a **\$1,613 t/oz gold price**, which is at the mid-point between the long run (17 years) median gold price and the **current spot price of ~\$1,818 t/oz**.

Our value range is \$6.68 to \$7.03 p/s suggesting 88-97% upside. The stock is up ~78% since our initiation note of Sep 28, 2022.

Gold – PPTA's superior project economics: The SGP, is located along the eastern edge of the Idaho Batholith, within the Central Idaho Mineral Belt. There are 3 primary deposits mined as 3 separate open pits and an additional 3m MT of historical tailings at >1.0 gpt.

Antimony (Sb) - PPTA could reduce US critical minerals supply chain risk: PPTA plans to supply ~35% of US Sb demand. Antimony is a critical mineral used in renewables, LDES, defense (ammunition et al), and fire-retardant materials. Currently, China and Russia dominate global antimony supply, controlling more than 75% of production. PPTA has national strategic value in its ability to become the sole US antimony domestic source of mined production.



Defense – On Dec 19, 2022 Perpetua received an award of up to \$28.4m under the Defense Production Act (DPA) for critical minerals, i.e. **Antimony trisulfide**. On Sept 12, 2022, Perpetua announced a \$200k grant by the US Department of Defense (DoD) (through Defense Logistics Agency (DLA)) for two study programs - each to be completed over 12 months – to evaluate PPTA's military-grade antimony trisulfide resources to see if they meet military specifications (Mil-Spec).

Renewables - Antimony's unique properties make the semi metallic element a key resource in renewable energy (solar panels and wind turbines).

Long Duration Energy Storage (LDES) - PPTA's partner Ambri Inc. is rapidly commercializing an Sb-based liquid battery suitable for long-term energy storage. **Ambri's** use of antimony delivers a low-cost technology and a system that avoids degradation by fully consuming the negative electrode.

Healthcare - Although antimony (Sb) is currently used sparingly in medicine, it has beneficial effects and we expect healthcare AI iterative learning techniques to reveal more uses. Today Sb compounds (meglumine antimonate and sodium stibogluconate) are the principal medications for treating leishmaniasis (kala-azar), caused by a protozoan parasite.

ESG and Sustainability impact on valuation - PPTA is a leading exemplar within the junior mining space for ESG/Sustainability. The emphasis on ESG will lower its cost of capital through reduced risk and greater competition from investors. An ESG culture will improve operational margins through better monitored process and mindset. As we approach production this long-term investment will come into play, enhancing our valuation range.

Since our <u>initiation note</u> PPTA also completed its water quality improvements at Stibnite improving Hennessy Creek diversion channel to prevent leakage, removing legacy waste from Defense Mineral Exploration Administration (DMEA) waste rock dump from along the East Fork of the South Fork of the Salmon River (EFSFSR), and creating a lined diversion for surface water around Smelter Flats.

Catalysts

Final EIS 2H23E; Final permitting decision end 23E/beginning 24E; Rising gold price; Rising antimony demand / supply tightening (ammunition usage and innovation (EVs / clean energy); Successful Mil-Spec results from DoD project.



Supporting the US defense supply chain

PPTA's DPA funding and DoD grant will support the US' re-introduction of domestic antimony production to reduce reliance on foreign supply chains. Antimony is used in a variety of US military applications such as ammunition, batteries and flame retardants. The Russia-Ukraine war has created a sense of urgency for the US to reinforce its weapons supply chain.

Since the start of the war, the US has committed \$27bn+ in military equipment and supplies to the Ukraine. This has only evidenced the US' shortfall of weapon inventory and the need to speed up replenishment (Center for Strategic and International Studies - CSIS). According to the study, the US' military would not be able to withstand a potential conflict or major war with China over Taiwan. The US currently has a backlog of \$19bn+ for arms to Taiwan.

According to the CSIS, the US continues to evoke "risk averse, inefficient and sluggish" efforts in regard to its industrial base, in addition to workforce shortages, obsolete production lines and supply chain disruptions. While this may be the case, the steps that the US government has taken in order to promote PPTA's operations are evidence that the perspective is changing and change is accelerating.

The Biden administration plans to ask Congress for the largest ever Pentagon/national defense budget for 2024 (release date March 9th, 2023), expected to be higher than the \$858bn 2023 budget. The Pentagon is preparing itself to be able to fight two large-scale conflicts at the same time.

The US government procures antimony through private industry sources and the amount of antimony needed may vary based on factors such as military spending, technological advancements, and global supply and demand.

As the only known economic reserve of antimony in the US, Perpetua we position PPTA as a US national strategic asset. In order to boost domestic munition production and reduce strategic risk, the US will need to rely on domestic antimony investments as well as foreign allies, rather than on China or Russia. (The US has been producing antimony as a by-product of lead and zinc mining operations however, it currently imports 90%+ of its antimony).

Based upon the proposed defense budget, strategic concerns, geopolitics, electrification and technological innovation, we expect rising US demand for antimony.



Valuation

Exhibit 1: PPTA WACC, DCF and Value Range

ACF est. \$ (m)	2027E	2028E	2029E	2030E	2031E
Revenue	628	876	958	958	1,124
EBITDA	435.40	675.99	729.52	729.52	876.58
Net Income	315.8	490.4	529.2	529.2	635.9
FCF	435.37	675.96	729.49	729.49	876.55
CPS (diluted) (USD)	6.60	10.25	11.06	11.06	13.29

We see fair value of PPTA at USD 6.86 per share (fully diluted).

Stibnite Gold WACC Calc	
Pre-tax cost of debt	0.1%
ETR	26.5%
After-tax cost of debt	0.0%
Current Leverage	0.1%
Debt/(Cash)	0.1
Equity	224.3
Target Leverage	30.0%
D / (D+E)	23.1%
ACF β adj levered	1.5
rf	2.0%
ERP	5.9%
Cost of equity	10.9%
Risk adj.	3.2%
WACC	11.6%
Note: Successful issue of draft EIS a permitting will significantly reduce	

Valuation Range NPV Stibnite Gold 416.29 NPV FCF (\$m) 416.29 Net Debt/(Cash) 36.09 Fair Value (\$m) 452.26 NoSh (m) 63.01 NoSh (diluted) (m) 65.97 Intrinsic Value Per Share USD 6.86 Close Price USD 3.56 6.68 VR (low - high) 7.03 5.00% **VR** Spread Implied VR Return (low - high) 87.7% 97.4%

Note: implied value range in this ACF research note is based upon diluted shares in issue at the date of this note.



We expect to release further value upon the achievement of major milestones. (DoD \$200k grant for DLA study programs).

Sensitivity Analysis

WACC - ACF's valuation is highly conservative. We have factored in a risk adjustment, producing a WACC of >11.9% to account for the facts that Perpetua is not yet permitted and is non-revenue generating, first production is expected in 2027E. ACF has reduced its WACC since our <u>initiation note of Sep 28, 2022</u> to account for the SDEIS comment period closing on time (Jan 10, 2023), the \$28.4m DPA critical minerals award (Dec 19, 2022) and completion of the 2022 field program.

Metals Price Deck - We use a highly conservative metals price deck taking the half-way point for gold between the 17-year median of Au \$1,402.55 t/oz and the current spot price of ~\$1,845 t/oz to give an Au ~\$1,613 t/oz. Ag \$19.7 t/oz (2% above the FS assumption) and a price assumption for Sb of \$4.9 lb vs. the average 2022 price of \$6.30 lb. Our price deck formula does not capture self-evident long-term structural changes in demand, which will push long term median prices up.

Production and Grades - Our total production estimate is achieved by declining the 2020 FS grades by 5% to account for margins of error.

Opex and Inflation – We have applied inflation rates in the region of 10-15% in the early years of our opex forecasts. In the later years we have assumed that higher energy prices and net zero carbon targets will drive innovation as has happened during previous energy price shocks. Between now and the end of mine life (20 years) we expect compensatory operational savings to materialise via technological innovation, bringing our total project opex in line with the FS. We expect to revisit our inflation assumptions regularly.

Value Range - When we substitute our estimates in the DCF valuation this gives us a PPTA intrinsic value fully diluted of US\$ 6.86. Assuming a standard deviation of 5%, our fully diluted valuation range is US\$ 6.68 to 7.03 per share, suggesting an upside of 88%-97% vs. the close price. This valuation reflects that the project is not yet at construction decision.

Future Valuation Upgrades - we anticipate releasing valuation increases after successful major milestones.



Exhibit 2: Valuation sensitivity to Au/Sb/Ag Prices and WACC

	Sha	re Price					
	Gol	d Price (\$/t oz	·.)				
		1,513	1,563	1,613	1,663	1,713	(\$/oz)
	10%	7.52	8.48	9.44	10.40	11.36	
(%	11%	6.32	7.20	8.07	8.95	9.83	
WACC (%)	12%	5.24	6.05	6.86	7.66	8.47	
AC.	13%	4.28	5.02	5.76	6.51	7.25	
≥	14%	3.42	4.11	4.79	5.47	6.16	
	15%	2.66	3.29	3.92	4.55	5.18	
	16%	1.98	2.56	3.14	3.72	4.30	
		re Price	.				
	Ant	imony Price (/± /// \
	4.40/	3.9	4.4	4.9	5.4	5.9	(\$/lbs)
	11%	7.36	7.72	8.07	8.43	8.79	
<u> </u>	11%	7.36	7.72	8.07	8.43	8.79	
Ö	12%	6.20	6.53	6.86	7.18	7.51	
WACC (%)	13%	5.16	5.46	5.76	6.07	6.37	
>	14%	4.23	4.51	4.79	5.07	5.35	
	15%	3.40	3.66	3.92	4.18	4.44	
	16%	2.66	2.90	3.14	3.38	3.62	
		re Price					
	Silv	er Price (\$/t o					
		16	18	20	22	24	(\$/oz)
	11%	7.98	8.03	8.07	8.12	8.17	
(%	11%	7.98	8.03	8.07	8.12	8.17	
WACC (%)	12%	6.77	6.81	6.86	6.90	6.94	
/AC	13%	5.69	5.73	5.76	5.80	5.84	
>	14%	4.72	4.76	4.79	4.83	4.86	
	15%	3.85	3.89	3.92	3.95	3.98	
	16%	3.08	3.11	3.14	3.17	3.20	

Source: ACF Research Estimates; Companies reports; Refinitiv.

Exhibit 3: Metals/minerals price deck

Metal/Currency	Price (P)	Price PPTA	% ∆	Av. price	Av. price	Av. P 2022	Spot P	Spot P vs.
	assmp. for this	FS on		2021	2022	vs. ACF		ACF assmp.
	Note	12/22/2020				assmp. % Δ		% ∆
Au (\$/Troy oz)	1,613	1,600	0.78%	1,799	1,802	11.74%	1,818	12.73%
Sb (\$/lb)	5	4	40.71%	5	6	27.92%	5	3.35%
Ag (\$/Troy oz)	20	20	-1.66%	25	22	10.63%	20	2.12%

Source: ACF Research Estimates; Macrotrends.net; Metalsdaily.com.



Peer Group Comparators - Gold

Exhibit 4: Trailing PPTA peer group metrics - Gold resources only

TTM Metrics / Company Name	Market	Tkr	MCAP US\$(m)	EV \$(m)	EV / REVS N	l+l+l (Moz)	MCAP / M+I+I	EV / M+I+I
Perpetua Resources	XNAS	PPTA	314	285	N/M	7.28	43.10x	39.08x
Artemis Gold	XTSX	ARTG	584	536	N/M	11.92	49.04x	44.99x
Skeena Resources	XNYS	SKE	555	536	N/M	4.02	138.01x	133.20x
Integra Resources	XNYS	ITRG	57	46	N/A	3.05	18.84x	15.22x
Marathon Gold	XTSE	MOZ	233	115	N/A	5.06	46.10x	22.79x
Average							62.99x	54.05x
Median							62.99x	54.05x

Source: ACF Research Estimates; Companies reports; Refinitiv.

This peer group is made up of junior gold explorations companies with assets in Canada and the US. These are arguably PPTA's closest and most relevant peers in our view based on PPTA's primary asset. In exhibit 4 above, we have calculated only the gold resources (M+I+I).

The peer group table shows that Perpetua is discounted compared to its peers that have a similar market cap. When we observe the MCAP/M+I+I and the EV/M+I+I multiples, given the stage PPTA is in (i.e. recent milestones highlighted in this note) it is still undervalued compared to its peers that are in the same pre-permitting stage (ARTG, SKE) although PPTA has the second highest value of resources, after ARTG. PPTA's strategic value is not recognized by the market, but in our view, it will eventually close the valuation gap.

PPTA is the only known economic reserve of antimony in the US. Finding a peer based on that asset was not going to be comparable as we would have had to choose Chinese companies, which are far more advanced in the mining stage, or companies representative of the antimony vertical integration. PPTA's main asset is gold, which is what is currently driving its valuation. (*PPTA reserves and resources in the tables include antimony because the deposits contain zones with elevated antimony-silver mineralization, which is not classified separately from gold and is reported it if lies within gold Mineral Resource estimates.)

PPTA does not make up a constituent of our average or median values in the peer group metrics at the bottom of exhibit 4 above We have excluded PPTA from these values to make the comparison with the rest of the peer group as clean and undistorted as possible.



Peer Group Comparators - Gold

Exhibit 5: Trailing PPTA peer group metrics – Total resources

TTM Metrics / Company Name	Market	Tkr	MCAP US\$(m)	EV \$(m)	EV / REVS M	l+l+l (Moz)	MCAP / M+I+I	EV / M+I+I
Perpetua Resources	XNAS	PPTA	314	285	N/M	7.93	39.58x	35.89x
Artemis Gold	XTSX	ARTG	584	536	N/M	13.91	42.02x	38.56x
Skeena Resources	XNYS	SKE	555	536	N/M	6.48	85.66x	82.67x
Integra Resources	XNYS	ITRG	57	46	N/A	4.93	11.65x	9.42x
Marathon Gold	XTSE	MOZ	233	115	N/A	5.06	46.10x	22.79x
Average							46.36x	38.36x
Median							46.36x	38.36x

Source: ACF Research Estimates; Companies reports; Refinitiv.

In exhibit 5 above, we have calculated total resources (M+I+I), which includes silver and antimony for Perpetua. For the other peers this includes: silver for Integra, gold equivalent and silver for Artemis, gold equivalent and silver for Skeena (Marathon only has gold resources).

When we observe the MCAP/M+I+I and the EV/M+I+I multiples of total resources, given the stage PPTA is in (i.e. recent milestones highlighted in this note) it is significantly undervalued compared to its peers that are in the same pre-permitting stage (ARTG, SKE). Antimony de-risks the project because it is a unique selling point for the company, providing a further indication of PPTA's competitive advantage as the US' national strategic asset.

In exhibit 6 below, we have calculated gold resources only as a percent of total resources for Perpetua and its gold peers, as well as the price of gold as a percent of total resources if it were valued at the current gold spot price of \$1,818 t/oz, Ag \$20 t/oz and Sb \$4.9 lb.

Exhibit 6: Gold as a % of total AuEq resources

Company Name	Market	Tkr	Gold (M+I+I Moz)	Total (M+I+I Moz)	Gold (% of total Moz)	Gold (\$m)	Total (\$m)	Gold (\$m % of total)
Perpetua Resources	XNAS	PPTA	7.28	7.93	91.80%	13,432	14,808	90.71%
Artemis Gold	XTSX	ARTG	11.92	13.91	85.69%	21,987	24,703	89.01%
Skeena Resources	XNYS	SKE	4.02	6.48	62.04%	7,419	9,451	78.49%
Integra Resources	XNYS	ITRG	3.05	4.93	61.87%	5,625	8,635	65.14%
Marathon Gold	XTSE	MOZ	5.06	5.06	100.00%	9,327	9,327	100.00%

Source: ACF Research Estimates; Macrotrends.net; Metalsdaily.com.



Peer Group Selection - Gold

Artemis Gold (TSX:ARTG listed) is a Canadian mining company focused on the exploration, development and production of gold and other precious metals in British Columbia, Canada. The company's flagship project Blackwater is a large-scale openpit gold and silver mine in the development stage with construction estimated to begin in 2023. In the first 5 years. The project has a project life of mine (LoM) of 17 years, the mine is forecasted to produce an average of 485k oz of gold/year over the first nine years of operation

Skeena Resources (**NYSE:SKE** listed) is a Canadian mining company focused on the exploration, development and production of gold, silver and copper in British Columbia, Canada. The company has two projects: Eskay Creek and Snip. Skeena's Eskay Creek mine has an historical production of 3.3m+ oz of gold and 160m+ oz of silver, with plans to expand resources and advance the project to production.

Integra Resources (NYSE:ITRG listed) is a Canadian mining company focused on the exploration, development and production of gold and silver in North America, primarily Idaho, USA. The company has two projects: DelAmar and Florida Mountain. The DeLamar project is a high-grade gold and silver deposit with significant potential for exploration and a mineral resource estimate of 4.4m oz AuEq.

Marathon Gold Corp. (TSX:MOZ listed) is a Canadian mining company focused on the exploration and development of gold in Newfoundland and Labrador, Canada. Marathon's primary asset, the Valentine Gold Project, includes four main deposits: Leprechaun, Marathon, Sprite and Victory. Permitting for the Valentine Gold Project was issued in Aug 2022 following the EA release, with early works construction commenced in Oct 2022. The project has a total M+I+I estimated resources of 5Moz of Au.



Peer Group Comparators - Antimony

Exhibit 7: Trailing PPTA peer group metrics - Antimony

TTM Metrics / Company Name	Market	Tkr	MCAP US\$(m)	EV \$(m) E	V/EBITDA N	MCAP / FCF	EV / FCF	EBITDA M%	FCF M%
Perpetua Resources	XNAS	РРТА	314	285	N/M	N/M	N/M	N/M	N/M
Mandalay Resources	XTSE	MND	173	156	1.74x	4.23x	3.81x	46.67%	21.29%
Albemarle Corp.	XNYS	ALB	29,171	31,021	10.81x	N/M	N/M	39.21%	N/M
Solvay SA	XBRU	SOLB	11,865	13,784	3.89x	11.03x	12.81x	20.91%	6.35%
Clariant AG	XFRA	CLRS	5,321	6,109	N/A	6.29x	7.22x	15.77%	15.33%
Average					5.48x	7.18x	7.95x	30.64%	14.32%
Median					5.48x	7.18x	7.95x	30.64%	14.32%

Source: ACF Research Estimates; Companies reports; Refinitiv.

This peer group represents antimony vertical integration, including companies that mine/produce minerals or chemicals including antimony by-products for various applications, e.g., lead-acid batteries (LAB), flame-retardant materials and alloys.

These peers provide an indication as to what valuation PPTA could achieve were it measured solely on its strategic antimony asset. Exhibit 5 shows that these antimony peers have either outperformed or an in line with a major index (Nasdaq).

Exhibit 8: PPTA antimony peer group price relative versus Nasdaq



Sources: ACF Research Estimates; Refinitiv.



Peer Group Selection - Antimony

Mandalay Resources Corporation (TSX:MND listed) is a Canadian mining company producing gold, silver and antimony with operations in Australia and Sweden. Mandalay produces antimony as a by-product of gold and silver mining operations in Australia, and gold concentrate in Sweden. The company focuses on implementing sustainable mining practices while working closely with its local communities.

Albemarle Corporation (NYSE:ALB listed) is a global specialty chemical company that produces a wide range of chemical products, including antimony-based compounds and flame retardants headquartered in Charlotte, NC, USA. Albemarle produces antimony trioxide, which is a flame retardant used in a variety of plastics, textiles, and other materials. The company's antimony trioxide product is marketed under the brand name Martinal, and it is one of the most widely used flame retardants in the world. Albemarle's antimony-based products are produced in the US and China.

Clariant AG (CLN.SW listed) is a global specialty chemicals company producing antimony-based chemicals and phosphorous-based flame retardants based in Switzerland. Clariant produces antimony trioxide, which is used in flame retardants in various industries, such as textiles, plastics, and electronics under the brand name Exolit, and the product is marketed as a high-quality flame retardant with excellent performance characteristics. Clariant's antimony-based products are produced at the company's manufacturing facilities around the world, including Europe, Asia, and North and South America.

Solvay SA (**SOLB.BR** listed) is a publicly listed company headquartered in Brussels, Belgium and it operates in four segments: Materials, Chemicals Solutions and Corporate & Business Services. Solvay incorporates antimony in its formulations - specializing in cleaner solutions for the automotive and aerospace industries, facilitating the shift to electric and hybrid vehicles in automotive and meeting the needs for advanced solutions to produce more fuel-efficient aircrafts in aerospace.



Financial Projections

P&L \$ (m)	2027E	2028E	2029E	2030E	2031E
Revs	628	876	958	958	1,124
gr%		39%	9%	0%	17%
Total Expenses	-193	-200	-229	-229	-247
EBITDA	435	676	730	730	877
% Revs	69%	77%	76%	76%	78%
FV adj.	0	0	0	0	0
% Revs	N/M	N/M	N/M	N/M	N/M
EBIT	435.3	675.9	729	729	877
EBT	435	676	729	729	877
% Revs	NM	1	1	1	1
ETR	0	0	0	0	0
NI	316	490	529	529	636
% Revs	NM	56%	55%	55%	57%
Adj EPS (p)	4.8	7.4	8.0	8.0	9.6
Basic EPS (p)	5.0	7.8	8.4	8.4	10.1
Diluted EPS (p)	4.8	7.4	8.0	8.0	9.6
Balance Sheet \$ (m)	2027E	2028E	2029E	2030E	2031E
PP&E	0	0	0	0	0
Total Fixed Assets	0	0	0	0	0
Current assets	1	2	2	2	2
Cash	235	726	1,256	1,786	2,424
Total Current Assets	236	728	1,257	1,788	2,426
Total Assets	236	728	1,257	1,788	2,426
Creditors	3	4	4	4	5
Other liabilities	0	0	0	0	0
Loans	0	0	0	0	0
Total Liabilities	13	7	7	7	8
Net Assets	223	721	1,250	1,780	2,418
Share Capital	615	615	615	615	615
Accum. Profit/(loss)	0	0	0	0	0
Total Equity	223	721	1,250	1,780	2,418
Total Equity & Liabilities	236	728	1,257	1,788	2,426
Basic NAV (p)	354	1,144	1,984	2,825	3,838
Diluted NAV (p)	0	0	0	0	0
Cash Flow \$ (m)	2027E	2028E	2029E	2030E	2031E
EBT Profit/(loss)	435	676	729	729	877
Finance costs	2	2	3	3	0
FV adj. + Other adj.	0	0	0	0	0
Cash Taxes	-120	0	0	-120	-186
WCap change	-4	1	0	0	0
Net CFO	312	491	529	529	636

Source: ACF Research Estimates; Companies reports.



Notes [Intentionally Blank]



INDEPENDENCE & DISTRIBUTION

ACF Equity Research Ltd is a provider of issuer-pays research with a clearly defined independent ethic. ACF produces accurate, clear, focused research aimed at a professional investment audience. ACF has excellent distribution capabilities and always aims to provide access without restriction to the widest professional audience. ACF offers a range of additional services to support its clients.

DISCLAIMER

This communication is for informational purposes only. It is not intended as an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. [The opinions expressed in this report herein do not take into account individual investor circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. The recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein.] ACF Equity Research Ltd has based this document on information obtained from sources it believes to be reliable, but which it has not independently verified. Neither ACF Equity Research Ltd. nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice. [Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by ACF Equity Research Ltd. with respect to future performance. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.]

IMPORTANT DISCLOSURES FOR U.S. INVESTORS

This research report was prepared by ACF Equity Research Ltd., a company authorized to engage in securities activities in the United Kingdom. ACF Equity Research Ltd. is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended. Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through, a registered broker-dealer in the United States. The analyst who prepared this research report is not registered or qualified with the Financial Industry Regulatory Authority ("FINRA") and may not be associated with a U.S. broker dealer and as such, would not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

[Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.]

LEGAL NOTICE

This report is for authorized use by the intended recipient(s) only. It may contain proprietary material, confidential information and/or be subject to legal privilege. No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of ACF Equity Research Ltd. and ACF Equity Research Ltd. accepts no liability whatsoever for the actions of third parties in this respect.

IMPORTANT ADDITIONAL DISCLOSURES FOR U.K. INVESTORS

The information in this report has been prepared by ACF Equity Research Ltd (ACF). The research is published for information purposes only. It is not intended as an offer or solicitation for the purchase or sale of any securities or any financial instruments.

ACF has based this document on information obtained from sources it believes to be reliable but which it has not independently verified. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice. Any comments or statements made herein do not necessarily reflect those of ACF Equity Research Limited. The material should not be regarded by recipients as a substitute for the exercise of their own judgment. Past performance does not guarantee future performance.

The analyst(s) responsible for covering the securities in this report receive compensation based upon, among other factors, the overall profitability of ACF which may, from time to time, solicit business from any of the companies referred to in this report. The analyst(s) responsible for covering securities in this report may not hold a position in any or related securities in this report in ACF's sector universe on in any other sector in which ACF carries out research. The company does not hold any position in the securities mentioned in this report.

This research report and its contents are intended for professional investors and not for retail investors. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of the investment research. ACF Equity Research Limited is authorised and regulated by the Financial Conduct Authority. However the contents of this research report are produced as if ACF Equity Research Limited is unregulated and consequently this report does not contain investment recommendations or ratings.

ACF, its directors, employees and agents accept no liability whatsoever for any loss or damage of any kind arising out of the use of all or part of these materials. The information in this report is provided with the understanding that ACF is not acting in a fiduciary capacity. Certain laws and regulations impose liabilities which cannot be disclaimed. This disclaimer shall in no way constitute a waiver or limitation of any rights a person may have under such laws and/or regulations. Copyright © 2020 ACF Equity Research all rights reserved. Additional information is available upon request.

Copyright 2020 ACF Equity Research Ltd. All rights reserved.

ACF Equity Research Limited, 125 Old Broad Street, London, EC2N 1AR, U.K.

Tel: +44 (020) 7558 8974

Website: www.acfequityresearch.com